novo nordisk semaglutide shortage The FDA Wins. The OFA Loses. And Is Off the List for Good Rethinking Obesity: Wegovy | PharmExec

The difference is the dose for weight loss is more than double the dose for diabetes

Therefore, some follow-up data regarding body weight were missing or self-reported

However, if your current dose is effective and you're achieving weight loss, there's no need to raise it

Individuals with a history of gastrointestinal issues, thyroid conditions, or hypersensitivity to GLP-1 receptor agonists may be more susceptible to side effects

Tirzepatide or Semaglutide Monotherapy for Methamphetamine Use Disorder There are no FDA approved medications for stimulant use disorder and the number of overdoses from stimulants has risen dramatically in the past 5 years